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Objective: Certain intra-type variants of HPV16 have been shown to be associated with an increased risk
of developing high grade cervical disease, but their potential association is confounded by apparent geo-
graphic and phylogenetic lineage dependency. The objective of this study was to evaluate the relationship
between HPV16 sequence variants and cervical disease stage in monospeciﬁc infection samples from a
single lineage (European, EUR) in England.
Methods: One hundred and twelve women singly infected with HPV16 and displaying normal and abnor-
mal cytology grades were selected. An 1187 bp fragment encompassing the entire LCR and a portion of
the E6 open reading frame was sequenced to identify intra-type variants. Intra-type diversity was esti-
mated using Shannon entropy.
Results: Almost all samples (110/112; 98%) were assigned to the EUR lineage, one sample was classiﬁed
as European-Asian (EAS) and another African (Afr1a). The mean pairwise distance of the EUR sequences
in this study was low (0.29%; 95%CI 0.13–0.45%) but there were nevertheless several sites in the LCR
(n = 5) and E6 (n = 2) that exhibited a high degree of entropy. None of these sites, however, including
the T350G non-synonymous (L83V) substitution in E6, alone or in combination, were found to be
associated with cervical disease stage.
Conclusions: Despite using single infection samples and samples from a single variant lineage, intra-type
variants of HPV16 were not differentially associated with cervical disease. Monitoring intra-lineage, site-
speciﬁc variants, such as T350G, is unlikely to be of diagnostic value.
Crown Copyright  2014 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Persistent infection with oncogenic genotypes of genital Human
Papillomavirus (HPV) is associated with the development of cervi-
cal cancer, a signiﬁcant cause of morbidity and mortality of women
worldwide (Schiffman et al., 2007). There are about a dozen HPV
genotypes associated with the development of cervical disease
(Bouvard et al., 2009), differing in their relative contributions to
the overall prevalence of disease (Guan et al., 2012), with HPV16
displaying the highest prevalence worldwide and the strongest dis-
ease association. The underlying mechanisms that drive a minority
of HPV16 infections to persist, leading to the development of pre-
cancerous lesions and ultimately cervical cancer are poorly under-
stood. Principal viral cofactors include the oncoproteins, E6 and E7,
that drive cellular deregulation under the control of the upstreamLong Control Region (LCR) (Bernard, 2013; Moody and Laimins,
2010).
The DNA-based HPV genome is efﬁciently replicated by cell
polymerases with an error rate of ca. 1  108 base substitutions,
per site, per year (Chen et al., 2009) which is considerably lower
than for the HIV-1 RNA genome (ca. 1  103) for example
(Korber et al., 2000). Nevertheless, over millennia, the HPV genome
has diverged into genotypes and intra-genotype variants (Burk
et al., 2013), compounded by diversifying selection pressure(s)
(Chen et al., 2005). The intra-genotype variation of HPV16 appears
to be closely aligned with human migration patterns (Chan et al.,
1992), leading to the designation of pseudo-geographic lineages
based upon LCR diversity: European (EUR), European-Asian (EAS),
African 1 (Afr1a, Afr1b), African 2 (Afr2a, Afr2b), Asian-American
(AA1 and AA2) and North-American (NA), although the actual
geographical distribution of these lineage variants is somewhat
more complex (Cornet et al., 2012; Yamada et al., 1997).
It has been observed that Non-European variants of HPV16, par-
ticularly of the AA lineage, have a higher propensity for persistence
(Schiffman et al., 2010; Villa et al., 2000; Zuna et al., 2009), and
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disease (CIN2/3) (Xi et al., 1997, 2007). A recent meta-analysis of
worldwide HPV16 lineage distribution data conﬁrmed the associa-
tion of certain lineages with an increased risk of cervical disease
but also noted some geographical dependency to these associa-
tions (Cornet et al., 2013b). Within the EUR variant lineage, a
T350G substitution in the E6 gene leads to an altered amino acid
residue (L83V) and has been associated with HPV16 persistence
(Gheit et al., 2011) and cervical disease (Andersson et al., 2000),
though not in all cases (Chan et al., 2002; Cornet et al., 2013a;
Nindl et al., 1999; Zuna et al., 2009). Two recent meta-analyses
demonstrate that the E350 codon is associated with cervical dis-
ease but is likely to be geographically dependent (Cornet et al.,
2013b; Tornesello et al., 2011). The LCR is traditionally used to
ascertain the variant lineage of a sequence as this region contains
a number of lineage-dependent diagnostic markers (Cornet et al.,
2012), but data on the potential for an association of individual
sites within the LCR and cervical disease are limited. Some studies
have found an association with individual sites in the LCR (Chang
et al., 2013; Schmidt et al., 2001), while others have not
(Kammer et al., 2002), although the signiﬁcance of these observa-
tions have been confounded by the use of relatively small panels of
samples containing mixed lineages.
In addition, mixed infections are common throughout the
course of cervical disease (Guan et al., 2012). Few of these studies
have explicitly used, or separately analyzed, samples harboring a
single HPV type wherein the association between the HPV type
under evaluation and cervical disease can be made with some
conﬁdence.
The biological basis for the differential disease outcomes fol-
lowing infection by HPV16 lineage variants is unclear. The
HPV16 AA lineage variant and the EUR T350G (L83V) variant exhi-
bit an increased propensity to transform primary human foreskin
keratinocytes or induce apoptosis in organotypic raft cultures
in vitro compared to the HPV16 prototype (Niccoli et al., 2012;
Richard et al., 2010; Zehbe et al., 2011). HPV16 LCR variant lineages
have been shown to differentially drive transcriptional activity of
the p97 promoter (Kammer et al., 2000), as have other combina-
tions of site-speciﬁc variations within and outside the principal
transcriptional motifs in the LCR (Bernard, 2013; Lace et al.,
2009), although their impact individually is less certain (Lace
et al., 2009; Veress et al., 1999).
In this study, we evaluated LCR–E6 sequence variation within
the EUR lineage of HPV16 in single infection samples to understand
the distribution of such variation and its potential role in cervical
disease.2. Materials and methods
2.1. Samples
The present study made use of extracted DNA (archived at
25 C) from individuals singly infected with HPV16 (n = 112)
from a cohort of 4719 women attending cervical screening in Eng-
land wherein HPV genotyping was conducted using the LINEAR
ARRAY HPV Genotyping Test (Roche Molecular Diagnostics)
(Howell-Jones et al., 2010). Cytology samples were graded using
Dysplasia nomenclature (Schiffman et al., 2007; Sherman, 2003).
Under this system, cytology grades of moderate and severe dyspla-
sia are equivalent to a designation of High grade Squamous Intra-
epithelial Lesion (HSIL) using Bethesda nomenclature. Similarly,
grades of borderline (Atypical Squamous Cells of Undetermined
Signiﬁcance; ASCUS) and mild (Low grade Squamous Intraepithe-
lial Lesion; LSIL) dysplasia are equivalent to the indicated grades
using the Bethesda system. For the purposes of analysis, cytologygrades of normal, borderline and mild dyskaryosis were catego-
rized as low grade (controls) and cytology grades of moderate
and severe dyskaryosis as high grade (cases). Accompanying histo-
logical data were only available for ca. 15% of the cytology samples
in the total study cohort. Amongst these, CIN2+ was diagnosed in
18% of borderline or mild dyskaryosis and in 79% of moderate or
severe dyskaryosis. The median age of the individuals for which
samples were used in the present study was 36 (inter-quartile
range, IQR, 29–46). There was no signiﬁcant difference between
the ages of the individuals in the low grade (controls) group
(median 34; IQR 27–46) and those in the high grade (cases) group
(median 39; IQR 32–47) (p = 0.348). The testing of residual, anon-
ymized DNA extracts for the purposes of improved understanding
of cervical disease was approved by the Harrow Research Ethics
Committee, UK (08/H0719/17).
The full genome HPV16 plasmid was kindly provided by the
German Cancer Research Centre, Heidelberg, Germany (E.M.
de Villiers). Site-speciﬁc numbering was made according to the
HPV16 reference sequence, K02718 (http://pave.niaid.nih.gov).
2.2. LCR–E6 PCR and sequencing
HPV16 samples were ampliﬁed in a single 1329 bp fragment
with primers 16-F101 (50-ACCCACCACCTCATCTACC-30) and
16-R20 (50-TGCAACAAGACATACATCGACC-30), annealing at posi-
tions 7100–7118 and 524–503, respectively. Template ampliﬁca-
tion was performed in a 25 lL reaction mix containing Kapa HiFi
HotStart ReadyMix (Kapa Biosystems), 5 pmol of each primer and
5 lL of template DNA sample under the indicated cycling conditions
(95 C for 5 min followedby 40 cycles of 98 C for 20 s, 63 C for 15 s,
72 C for 2 min, and ﬁnal elongation at 72 C for 5 min) on a PTC-200
thermal cycler (MS research). The resulting PCR product was evalu-
ated for its molecular weight using a DNA mass ladder (Invitrogen)
and GelAnalyzer software (www.gelanalyzer.com) and sequenced
using 5 pmol of each indicated sequencing primer 16-F101,
16-R20, 16-F2 (50-GAAACCGGTTAGTATAAAA GCAGAC-30, nucleo-
tides 53–77), 16-F480 (50-AATGTGTTTTTTTAAATAG-30, nucleotides
7481–7499), 16-R28 (50-AGTTGTTTGCAGCTCTG TGA-30, nucleo-
tides 169–149), and 16-R38 (50-GTAAG GCGTTGGCGCATAGTG-30,
nucleotides 7686–7666). All primers were designed using Oligo
Explorer software (www.genelink.com). The HPV16 plasmid was
re-sequenced during the study (n = 10) with 100% identity. In addi-
tion, 22 clinical samples were re-ampliﬁed and re-sequenced to
ensure quality of the procedure and integrity of the data returning
100% identity to their initial sequences. The resulting sequence
fragment corresponds to an 1178 bp stretch covering the entire
LCR and the ﬁrst 427 bp of the E6 ORF. The accession numbers for
sequences generated in this study are KJ754940–KJ755051. They
comprise samples graded as cytologically Normal (No_1 to No_6;
KJ755002–KJ755007), and those exhibiting Borderline (Bo_1 to
Bo_9; KJ754940–KJ754948), Mild (mi_1 to mi_19; KJ754949–
KJ754967), Moderate (Mo_1 to Mo_34; KJ754968–KJ755001) or
Severe (Se_1 to Se_44; KJ755 008–KJ755051) dysplasia.
2.3. Phylogenetic and statistical analyses
EUR (n = 145) and non-EUR (n = 208) LCR–E6 HPV16 back-
ground sequences (Cornet et al., 2012) were downloaded from
the National Center for Biotechnology Information (NCBI; http://
www.ncbi.nlm.nih.gov/). Sequence alignments and Neighbor-Join-
ing (NJ) tree construction (500 bootstrapped replicates) were made
using MEGA v4.1 (Tamura et al., 2007). The average number of base
substitutions per site was based on the pairwise analysis of result-
ing sequence alignments including an estimate of standard error
(500 bootstrapped replicates) using the Maximum Composite Like-
lihood model (MEGA).
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Entropy One program (http://www.hiv.lanl.gov/content/sequence/
ENTROPY/entropy_one.html) (Korber et al., 1994). For comparison
purposes, a level of 5% site variation equates to an entropy score of
ca. 0.2.
The Fisher’s exact test was used to test for differences in propor-
tions of variants between cases and controls with crude odds ratios
(95%CI) also given. Based on an equal distribution of prototype
(E350T) and variant (E350G) sequences overall (Cornet et al.,
2013b; Tornesello et al., 2011) we ascertained that 50 samples
from each of the cases and controls would be sufﬁcient to observe
a 50% difference in the distribution of the prototype and variant
sequences between the cases and controls (p < 0.05). The non-
parametric Mann–Whitney U test was used to examine the age
distribution within the cases and control cytology groups. Tests
were 2-tailed where appropriate and all tests were carried out
using Stata 12.1 (StataCorp, USA).3. Results and discussion
LCR–E6 sequences were generated from 112 liquid-based cytol-
ogy samples singly infected with HPV16. To ascertain the variant
lineage of these sequences, we initially aligned the LCR fragment
with 353 LCR sequences from a recent study on the global distribu-
tion of HPV16 variants (Cornet et al., 2012) (Fig. 1A). Almost all
(110/112, 98%) sequences from this present study were of the
European (EUR) variant lineage apart from one sequence thatReferenc
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Fig. 1. Phylogenetic distribution of LCR–E6 variants. Radial neighbor-joining phylogenet
(A) worldwide (n = 353) or (B) only background EUR variants (n = 145) (Cornet et al., 2
indicated by the key. Variant lineages are indicated as follows: European (EUR), European
and AA2) and North-American (NA). EUR branches indicated in gray had less than 50% boo
within each potential sub-cluster within the EUR variant lineage are indicated, with mialigned with the EAS variant lineage and one sequence that aligned
with the Afr1a variant lineage. These two sequences were removed
from further analysis. The remaining 110 EUR LCR–E6 sequences
were then aligned with 145 global EUR LCR–E6 sequences
(Cornet et al., 2012), to identify any potential sub-lineages
(Fig. 1B). Sub-clustering within the EUR lineage was only weakly
supported, with bootstrap values ranging between 50% and 70%.
We next used Shannon entropy to estimate site-speciﬁc varia-
tion (Fig. 2) which highlighted seven sites of signiﬁcant variation:
ﬁve in the LCR (G7193T, A7316C, T7449C, T7495C and G7520) and
two in the E6 gene (T109C and T350G). The distribution of these
variant sites was not clearly associated with any potential sub-
clustering of the EUR lineage (Fig. 1B), with few exceptions. For
example, T7449C was overrepresented in South Asian sequences
(65% of sequences; 95%CI 45–81%) compared to the average
(18%; 95%CI 14–23%; n = 255) (p < 0.001) and the T350G was
underrepresented in East Asian sequences (8%; 95%CI 2–38%) com-
pared to the average (44%; 95%CI 38–51%) (p = 0.014). These differ-
ences aside, EUR LCR–E6 variant sequences from England could be
found distributed throughout these potential EUR variant sub-clus-
ters (Fig. 1B). There were many other variant sites within the LCR
region (n = 48 sites; 0.9–3.6% of total sequences) and E6 gene
(n = 8; 0.9–2.7%), as exempliﬁed by entropy scores of <0.2
(Fig. 2), but with each represented by only a handful of sequences
within the panel. The mean pairwise distance of EUR LCR–E6
sequences in this study based on a single European country
(0.29%; 95%CI 0.13–0.45%; n = 110) was similar to the mean pair-
wise distance of the geographically dispersed EUR sequencese G7193T 
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Fig. 2. Site-speciﬁc intra-type sequence diversity. Variation within the 1178 bp fragment is estimated using Shannon entropy, wherein a value of zero reﬂects site-speciﬁc
conservation and higher values indicate increasing degrees of site-speciﬁc variation. A level of 5% variation equates to an entropy score of ca. 0.2. Site-speciﬁc variations above
this level are indicated by convention, numbered according to the reference HPV16 sequence, K02718. The boundaries of the LCR (red) and E6 (green) are indicated as are
major elements within the LCR, including the E2 binding site (E2BS), and transcriptional elements NF1, YY1, TEF1, AP1 and OCT1.
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these were considerably less diverse than the panel of background
HPV16 sequences regardless of variant lineage (1.34%; 0.99–1.69%;
n = 353) (Cornet et al., 2012).
The proportion of individual variant sites and sequence variants
displaying combinations of these major variant sites were exam-
ined in relation to cervical disease stage (Table 1). Of the ﬁve LCR
variant positions, G7193T and G7520A were present in around
65% and 69% of sequences, respectively, while A7316C, T7449C
and T7495C were present in around 10–15% of sequences, mostly
in combination with other LCR or E6 variant sites. G7193T
was found in 61% (95%CI 42–77%) of control sequences and 66%
(55–77%) of cases giving a crude OR of 1.28 (0.50–3.20;
p = 0.665). Similarly, G7520A was found in 64% (45–80%) of control
sequences and 71% (60–81%) of cases giving a crude OR of 1.43
(0.54–3.66; p = 0.501). G7193T (found in 65% of sequences) is
positioned within a TEF1 binding site and G7520A is within a
YY1 binding site. Variation within YY1 binding sites, including
G7520A, can affect individual site-speciﬁc binding of YY1
(Schmidt et al., 2001) but multiple YY1 binding site disruptions,
akin to those found in the major AA and Afr variant lineages, are
required to affect E6 promoter (p97) activity signiﬁcantly
(Kammer et al., 2000; Lace et al., 2009). In addition, variants
bearing both G7193T and G7520A substitutions did not alter the
ability of p97 to drive luciferase reporter expression in one study
(Veress et al., 1999).Table 1
Distribution of LCR–E6 variants in cases and controls.
Varianta Controls (n = 33)
n % 95%CI (%)
G7193T 20 61 42–77
A7316C 4 12 3–28
T7449C 6 18 7–35
T7495C 2 6 1–20
G7520A 21 64 45–80
T109C 2 6 1–20
T350G 15 45 28–64
Reference 8 24 11–42
G7520A alone 1 3 0–16
A7316C alone 4 12 3–28
G7193T/G7520A 3 9 2–24
G7193T/G7520A/T350G 7 21 9–39
G7193T/G7520A/T109C/T350G 2 6 1–20
G7193T/T7495C/G7520A 2 6 1–20
G7193T/T7449C/G7520A/T350G 6 18 7–35
G7193T/T7449C/G7520A/T109C/T350G 0 0 0–11
a Distribution of HPV LCR–E6 reference sequence, individual site variants regardless
T350G) and distribution of combinatorial variants for these seven major sites in cases andThe T109C substitution in E6 (found in 5% of sequences) is a
silent change that does not affect the Phe residue at codon 2.
Overall, the T350G (L83V) substitution was present in 41% (95%CI
32–51%) of sequences in this study which was lower than the
54% (51–57%) reported across Europe in a recent meta-analysis
(p = 0.009) (Tornesello et al., 2011). In this latter study, the
T350G variant was over-represented in cases compared to controls
(Tornesello et al., 2011), while in another analysis the T350G vari-
ant was under-represented in cases from Europe/Central Asia
while being over-represented in cases from South/Central America
(Cornet et al., 2013b). In the present study, the T350G substitution
was found in 45% (28–64%) of control sequences and 39% (28–51%)
of cases giving a crude OR of 0.77 (0.31–1.91; p = 0.534).
The data presented in this study represent the only available
information on HPV16 sequence variation and cervical disease in
the UK. While the use of single infection samples should have
reduced potential confounding factors in relation to the assign-
ment of disease status, the data overall suggest that no individual
or combination of LCR–E6 site variants, including T350G, displayed
any apparent association with cervical disease.
We identiﬁed samples singly infected with HPV16 using a
generic PCR and genotyping test (Howell-Jones et al., 2010). This
is a common approach and one of the more robust genotyping tests
(Eklund et al., 2013), but such generic genotyping tests cannot
exclude the potential for masking within mixed infections (van
Alewijk et al., 2013). The selection of samples exhibiting an appar-Cases (n = 77) OR 95%CI p value
n % 95%CI (%)
51 66 55–77 1.28 0.50–3.20 0.665
7 9 4–18 0.73 0.17–3.65 0.731
10 13 6–23 0.67 0.20–2.49 0.557
9 12 5–21 2.05 0.39–20.50 0.500
55 71 60–81 1.43 0.54–3.66 0.501
4 5 1–13 0.85 0.11–9.86 1.000
30 39 28–51 0.77 0.31–1.91 0.534
15 19 11–30 0.76 0.26–2.34 0.613
4 5 1–13 1.75 0.16–89.00 1.000
7 9 4–18 0.73 0.17–3.65 0.731
12 16 8–26 1.85 0.45–10.88 0.546
18 23 14–34 1.13 0.39–3.61 1.000
2 3 0–9 0.41 0.03–5.99 0.582
9 12 5–21 2.05 0.39–20.50 0.500
8 10 5–19 0.52 0.14–2.02 0.349
2 3 0–9 N/A N/A 1.000
of other site-speciﬁc variation (G7193T, A7316C, T7449C, T7495C, G7520A, T109C,
controls. OR, crude Odds Ratio; 95%CI, 95% conﬁdence intervals; N/A, not applicable.
12 L. Marongiu et al. / Infection, Genetics and Evolution 26 (2014) 8–13ent single HPV16 infection is a signiﬁcant improvement on the use
of unselected samples, wherein the potential impact of such mask-
ing is likely to be far higher. Nevertheless, there exists the possibil-
ity that a minority of samples in this study contained low levels of
other, non-HPV16, genotypes that could be the genotype(s) caus-
ally associated with the reported cervical disease phenotype.
Finally, although cytology samples are the primary sample type
collected during cervical screening and are readily amenable to
such an evaluation, the use of cytology samples to evaluate bias
in HPV variant distribution is potentially problematic given sam-
pling heterogeneity and the possibility of reporting inconsistency
between the overlapping cytology and histology stage designations
(Sherman, 2003).
4. Conclusions
The purpose of this study was to evaluate any potential rela-
tionship between HPV16 site-speciﬁc variants and cervical disease
stage in the context of singly infected samples, wherein the associ-
ation with disease can be assumed with some conﬁdence. Overall,
there appeared to be no individual LCR or E6 sites, or combinations
thereof, including the T350G (L83V) E6 substitution, that demon-
strated any signiﬁcant association with cervical disease stage.
Although these data suggest that LCR–E6 sequence variation per
se may not be a signiﬁcant driving force in the development of
cervical disease, improving the resolution of sequence variation
worldwide will nevertheless lead to a better understanding of
the diversity of HPV and may further illuminate important aspects
of HPV biology.
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